ArticleCancer diagnosis & prognosis
Patient-reported Outcomes of Adverse Events After Perioperative Chemotherapy for Breast Cancer: A Prospective Observational Study.
Article in Cancer diagnosis & prognosis. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background/Aim: Chemotherapy for breast cancer is associated with several adverse events (AEs), many of which are under-reported when assessed solely by physicians. Patient-reported outcomes (PROs) obtained Patients and Methods: Patients with operable breast cancer who received perioperative chemotherapy with a docetaxel/cyclophosphamide (TC) or anthracycline- and taxane-based chemotherapy regimen (A+T) were enrolled. A PRO-based questionnaire, prepared for this study and aligned with the Common Terminology Criteria for Adverse Events, was administered at the end of each patient's chemotherapy regimen and 6 months later. The questionnaire covered nausea, vomiting, oral mucositis, constipation, diarrhea, dysgeusia, insomnia, neuropathy, nail loss, and alopecia. The frequency and severity of each AE were compared between regimens, and longitudinal changes were analyzed. Results: A total of 115 patients (median age 50 years) were evaluated. Nausea, vomiting, mucositis, constipation, dysgeusia, insomnia, peripheral neuropathy, and nail loss were common at the end of the patients' chemotherapy regimens, but 6 months later the frequency of gastrointestinal symptoms had decreased. Several AEs persisted beyond 6 months; notably, neuropathy, dysgeusia, insomnia, and nail loss. Grade 3 symptoms persisted for neuropathy, and nail loss was confirmed to have increased at 6 months. Compared to the TC chemotherapy, peripheral sensory neuropathy persisted longer in the A+T group. Conclusion: PROs are thought to capture persistent symptoms that are often underestimated in conventional clinical practice. In the present breast cancer series, PRO-based monitoring revealed regimen-specific AE profiles and the persistence of neuropathy, dysgeusia, and nail changes beyond chemotherapy. These findings highlight the importance of monitoring not only during chemotherapy, but also in the months after the chemotherapy's completion, when patients continue to suffer from persistent symptoms. Incorporating structured PRO-based questionnaires into follow-up care may be crucial for optimizing supportive management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.